ExodusPoint Capital Management LP Invests $1.53 Million in Krystal Biotech, Inc. (NASDAQ:KRYS)

ExodusPoint Capital Management LP purchased a new position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 9,761 shares of the company's stock, valued at approximately $1,529,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. US Bancorp DE raised its position in Krystal Biotech by 8.7% during the fourth quarter. US Bancorp DE now owns 1,027 shares of the company's stock valued at $161,000 after buying an additional 82 shares during the period. Crossmark Global Holdings Inc. grew its stake in Krystal Biotech by 5.5% during the 4th quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company's stock valued at $362,000 after acquiring an additional 121 shares in the last quarter. Perigon Wealth Management LLC increased its holdings in shares of Krystal Biotech by 1.5% in the 4th quarter. Perigon Wealth Management LLC now owns 8,289 shares of the company's stock valued at $1,200,000 after purchasing an additional 123 shares during the period. Xponance Inc. increased its holdings in shares of Krystal Biotech by 9.5% in the 4th quarter. Xponance Inc. now owns 1,785 shares of the company's stock valued at $280,000 after purchasing an additional 155 shares during the period. Finally, Commonwealth Equity Services LLC lifted its position in shares of Krystal Biotech by 4.1% in the fourth quarter. Commonwealth Equity Services LLC now owns 4,866 shares of the company's stock worth $762,000 after purchasing an additional 190 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.

Remove Ads

Insiders Place Their Bets

In other news, CAO Kathryn Romano sold 750 shares of the company's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the transaction, the chief accounting officer now owns 12,604 shares of the company's stock, valued at approximately $2,208,472.88. This represents a 5.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the sale, the insider now directly owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. This trade represents a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 14.10% of the company's stock.

Krystal Biotech Stock Performance

Shares of Krystal Biotech stock traded down $2.59 on Tuesday, reaching $166.32. The stock had a trading volume of 43,334 shares, compared to its average volume of 294,532. The business's 50-day moving average price is $174.09 and its two-hundred day moving average price is $172.15. The stock has a market cap of $4.81 billion, a P/E ratio of 55.56 and a beta of 0.75. Krystal Biotech, Inc. has a fifty-two week low of $141.72 and a fifty-two week high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company had revenue of $91.10 million during the quarter, compared to analysts' expectations of $91.35 million. During the same period in the prior year, the company earned $0.30 earnings per share. The business's quarterly revenue was up 116.4% compared to the same quarter last year. As a group, equities analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price objective on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $221.00 price target on shares of Krystal Biotech in a research note on Friday, February 28th. Chardan Capital lifted their price objective on Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a research report on Thursday, February 20th. Citigroup upped their target price on Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a research report on Thursday, February 20th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $215.00 price target on shares of Krystal Biotech in a report on Thursday, February 20th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $220.00.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).